DK2190863T3 - New albumin binding compositions, methods and uses - Google Patents

New albumin binding compositions, methods and uses Download PDF

Info

Publication number
DK2190863T3
DK2190863T3 DK08786222.3T DK08786222T DK2190863T3 DK 2190863 T3 DK2190863 T3 DK 2190863T3 DK 08786222 T DK08786222 T DK 08786222T DK 2190863 T3 DK2190863 T3 DK 2190863T3
Authority
DK
Denmark
Prior art keywords
seq
albumin
polypeptide
binding
protein
Prior art date
Application number
DK08786222.3T
Other languages
Danish (da)
English (en)
Inventor
Lars Abrahmsen
Andreas Jonsson
Per-Ake Nygren
Jakob Dogan
Original Assignee
Affibody Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affibody Ab filed Critical Affibody Ab
Application granted granted Critical
Publication of DK2190863T3 publication Critical patent/DK2190863T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK08786222.3T 2007-07-31 2008-07-17 New albumin binding compositions, methods and uses DK2190863T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96261807P 2007-07-31 2007-07-31
EP07113533 2007-07-31
PCT/EP2008/059389 WO2009016043A2 (en) 2007-07-31 2008-07-17 New albumin binding compositions, methods and uses

Publications (1)

Publication Number Publication Date
DK2190863T3 true DK2190863T3 (en) 2015-11-30

Family

ID=40057660

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08786222.3T DK2190863T3 (en) 2007-07-31 2008-07-17 New albumin binding compositions, methods and uses

Country Status (11)

Country Link
US (2) US8937153B2 (https=)
EP (2) EP2190863B1 (https=)
JP (1) JP5718638B2 (https=)
CN (2) CN104710518A (https=)
AU (1) AU2008281913B2 (https=)
CA (1) CA2694139C (https=)
DE (1) DE08786222T1 (https=)
DK (1) DK2190863T3 (https=)
ES (1) ES2346178T3 (https=)
HK (1) HK1211040A1 (https=)
WO (1) WO2009016043A2 (https=)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2190863B1 (en) * 2007-07-31 2015-09-02 Affibody AB New albumin binding compositions, methods and uses
EP2437767B1 (en) * 2009-06-01 2015-07-08 MedImmune, LLC Molecules with extended half-lives and uses thereof
CA2789738C (en) * 2010-03-08 2021-03-09 Ge Healthcare Bio-Sciences Ab Immunoglobulin g fc region binding polypeptide
MX2012012383A (es) * 2010-04-30 2012-11-30 Sanwa Kagaku Kenkyusho Co Peptido para mejorar la bioestabilidad de una sustancia bioactica y sustancia bioactiva que tiene bioestabilidad mejorada.
CN103003296A (zh) 2010-07-09 2013-03-27 阿菲博迪公司 多肽
AU2011286024B2 (en) * 2010-08-02 2014-08-07 Macrogenics, Inc. Covalent diabodies and uses thereof
CA2812951A1 (en) 2010-09-28 2012-04-19 Amylin Pharmaceuticals, Llc Engineered polypeptides having enhanced duration of action
PT2621515T (pt) * 2010-09-28 2017-07-12 Aegerion Pharmaceuticals Inc Polipéptido quimérico de leptina de foca-ser humano com solubilidade aumentada
PL2643349T3 (pl) 2010-11-26 2020-03-31 Molecular Partners Ag Zaprojektowane białka z powtórzeniami wiążące się z albuminą surowicy
BR112013029892A2 (pt) * 2011-05-21 2016-12-20 Macrogenics Inc polipeptídeo, molécula de ligação a antígeno, diacorpo e uso de uma porção polipeptídica de uma proteína de ligação a soro desimunizada
JP6006309B2 (ja) * 2011-07-08 2016-10-12 アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
CN103957926B (zh) * 2011-07-08 2018-07-03 安米林药品有限责任公司 具有增强的作用持续时间和降低的免疫原性的工程改造的多肽
EP3511339B1 (en) 2012-02-20 2025-04-09 IPC Research, LLC Polypeptides binding to human complement c5
HK1208155A1 (en) * 2012-03-28 2016-02-26 Amylin Pharmaceuticals, Llc Transmucosal delivery of engineered polypeptides
JP2015512902A (ja) * 2012-03-28 2015-04-30 アフィボディ・アーベー 経口投与
JP2020033372A (ja) * 2012-03-28 2020-03-05 アフィボディ・アーベー 経口投与
CN104470944B (zh) 2012-05-25 2021-09-14 詹森生物科技公司 非天然共有白蛋白结合结构域
WO2014048977A1 (en) * 2012-09-25 2014-04-03 Affibody Ab Albumin binding polzpeptide
JP6440618B2 (ja) 2012-10-05 2018-12-19 アフィボディ・アーベー Ｈｅｒ３結合ポリペプチド
WO2014064238A1 (en) * 2012-10-25 2014-05-01 Affibody Ab Method for the separation of proteins containing an albumin-binding
CA2889037C (en) * 2012-10-25 2021-06-22 Affibody Ab Abd binding polypeptide
WO2014076179A1 (en) 2012-11-14 2014-05-22 Affibody Ab New polypeptide
US9255262B2 (en) * 2013-03-06 2016-02-09 Vision Global Holdings Ltd. Albumin-binding arginine deminase and the use thereof
USRE48805E1 (en) 2013-03-06 2021-11-02 Vision Global Holdings Ltd. Method for cancer targeting treatment and detection of arginine using albumin-binding arginine deiminase fusion protein
HK1213194A1 (zh) 2013-03-14 2016-06-30 Daiichi Sankyo Co., Ltd. 用於新型的结合蛋白质pcsk9
WO2014140882A2 (en) * 2013-03-14 2014-09-18 The Governing Council Of The University Of Toronto Scaffolded peptidic libraries and methods of making and screening the same
AU2014230018B2 (en) 2013-03-15 2018-02-22 Affibody Ab New polypeptides
MX2015014438A (es) 2013-04-18 2016-05-18 Armo Biosciences Inc Metodos de uso de interleucina-10 para tratar enfermedades y trastornos.
EP3010527B1 (en) 2013-06-17 2018-08-08 Armo Biosciences, Inc. Method for assessing protein identity and stability
BR112016003142A2 (pt) 2013-08-28 2017-10-17 Swedish Orphan Biovitrum Ab Publ ligação de polipeptídeos estáveis ao c5 do complemento humano
MX367423B (es) 2013-08-28 2019-08-21 Affibody Ab Polipeptidos de union a c5.
CN105658232A (zh) 2013-08-30 2016-06-08 阿尔莫生物科技股份有限公司 使用白细胞介素-10治疗疾病和病症的方法
CN120242030A (zh) 2013-11-11 2025-07-04 阿尔莫生物科技股份有限公司 将白细胞介素-10用于治疗疾病和病症的方法
US10167322B2 (en) 2013-12-20 2019-01-01 Affibody Ab Engineered albumin binding polypeptide
WO2015187295A2 (en) 2014-06-02 2015-12-10 Armo Biosciences, Inc. Methods of lowering serum cholesterol
AU2015296640B2 (en) 2014-07-30 2020-05-21 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
PL3193930T3 (pl) 2014-09-17 2019-12-31 Affibody Ab Nowe polipeptydy
WO2016060996A2 (en) 2014-10-14 2016-04-21 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
AU2015336101A1 (en) 2014-10-22 2017-04-20 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
EP3701969A1 (en) 2014-10-31 2020-09-02 NGM Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
EP3245224B1 (en) 2015-01-12 2020-07-15 Affibody AB Il-17a-binding polypeptides
WO2016126615A1 (en) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
WO2016179568A1 (en) * 2015-05-06 2016-11-10 Protomer Technologies, Inc. Glucose responsive insulins
US20160361415A1 (en) 2015-05-28 2016-12-15 Armo Biosciences, Inc. Methods of Using Interleukin-10 for Treating Diseases and Disorders
EA037478B1 (ru) 2015-08-04 2021-04-01 Дьюк Юниверсити Генетически кодируемые внутренне неупорядоченные полимеры-"невидимки" для доставки и способы их применения
KR20180038553A (ko) 2015-08-25 2018-04-16 아르모 바이오사이언시스 인코포레이티드 질환 및 장애를 치료하기 위한 인터류킨-10을 사용하는 방법
US11752213B2 (en) 2015-12-21 2023-09-12 Duke University Surfaces having reduced non-specific binding and antigenicity
CN107022031A (zh) * 2016-01-29 2017-08-08 中国人民解放军军事医学科学院微生物流行病研究所 融合蛋白HSA1-Vβ1及其应用
WO2017210476A1 (en) 2016-06-01 2017-12-07 Duke University Nonfouling biosensors
JP2020500150A (ja) 2016-09-23 2020-01-09 デューク ユニバーシティ 下限臨界溶液温度挙動を有する非反復かつ非構造的ポリペプチド
CN107952080A (zh) * 2016-10-14 2018-04-24 中国科学院过程工程研究所 一种肿瘤靶向多肽-药物偶联衍生物、其制备方法及应用
WO2018132732A1 (en) 2017-01-12 2018-07-19 Duke University Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly
WO2018213320A1 (en) 2017-05-15 2018-11-22 Duke University Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents
WO2019006374A1 (en) 2017-06-30 2019-01-03 Duke University ORDER AND DISORDER AS A DESIGN PRINCIPLE FOR STIMULI-SENSITIVE BIOPOLYMER NETWORKS
CN111164104A (zh) 2017-08-09 2020-05-15 麻省理工学院 白蛋白结合肽缀合物及其方法
WO2019071150A1 (en) * 2017-10-06 2019-04-11 University Of Utah Research Foundation FUSION PROTEIN FOR TARGETED THERAPY OF AUTOIMMUNE DISEASE
US20200239575A1 (en) * 2017-10-06 2020-07-30 University Of Utah Research Foundation A fusion protein for targeted therapy of autoimmune disease
WO2019147954A1 (en) * 2018-01-26 2019-08-01 Duke University Albumin binding peptide-drug (aibiped) conjugates and methods of making and using same
JP7545894B2 (ja) 2018-03-13 2024-09-05 アフィボディ アクティエボラーグ 新規足場に基づくポリペプチド
EP3788343B1 (en) 2018-04-30 2024-03-27 Duke University Stimuli-responsive peg-like polymer-based drug delivery platform
US11649275B2 (en) 2018-08-02 2023-05-16 Duke University Dual agonist fusion proteins
US12594347B2 (en) * 2018-09-07 2026-04-07 Duke University Nanoparticulate drug delivery systems
CN113710229B (zh) 2019-02-25 2026-01-06 芝加哥大学 用与抗炎剂连接的ecm亲和肽治疗炎症性和自身免疫性病症的方法和组合物
CA3138805A1 (en) 2019-06-04 2020-12-10 Johannes Schilling Designed ankyrin repeat domain with improved stability
US11512314B2 (en) 2019-07-12 2022-11-29 Duke University Amphiphilic polynucleotides
EP3785726A1 (en) 2019-09-02 2021-03-03 Biotest AG Factor viii protein with increased half-life
EP4017521A1 (en) 2019-09-02 2022-06-29 Biotest AG Factor viii protein with increased half-life
WO2021089695A1 (en) 2019-11-05 2021-05-14 Affibody Ab Polypeptides
US20230190881A1 (en) 2020-02-17 2023-06-22 Biotest Ag Subcutaneous administration of factor viii
EP3878515A1 (en) * 2020-03-09 2021-09-15 Hober Biotech AB Therapeutic agent targeting her2
WO2022098745A1 (en) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, delivery systems, and methods useful in tumor therapy
WO2022098743A1 (en) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, imaging, and therapeutic methods targeting folate receptor 1 (folr1)
KR20230123989A (ko) 2020-12-21 2023-08-24 애피바디 에이비 신규 폴리펩티드
EP4291251B1 (en) 2021-02-15 2025-02-19 Affibody AB Her2-binding polypeptide
AR128475A1 (es) 2022-02-08 2024-05-15 Affibody Ab Polipéptidos y proteínas de fusión con afinidad de unión por tslp
IL317049A (en) 2022-05-18 2025-01-01 Protomer Tech Inc Aromatic boron-containing compounds and related insulin analogs
TW202416938A (zh) 2022-08-10 2024-05-01 日商興和股份有限公司 親和體微胞(affibody micelle)藥物複合體
TW202448926A (zh) 2023-02-17 2024-12-16 比利時商艾伯霖克斯公司 結合新生兒fc受體之多肽
CN121038816A (zh) 2023-05-04 2025-11-28 阿菲博迪公司 新多肽
WO2025073871A1 (en) 2023-10-03 2025-04-10 Bicycletx Limited Bicyclic peptide ligand complexes specific for tfr1
TW202545983A (zh) 2024-01-25 2025-12-01 瑞典商艾菲博迪公司 新穎多肽
CN121041473A (zh) * 2024-05-29 2025-12-02 烟台蓝纳成生物技术股份有限公司 一种双功能性融合蛋白、放射性核素标记物及其应用
CN118666961B (zh) * 2024-08-23 2024-11-26 通化安睿特生物制药股份有限公司 人白蛋白特异结合多肽及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
FR2718452B1 (fr) * 1994-04-06 1996-06-28 Pf Medicament Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation.
FR2726471B1 (fr) * 1994-11-07 1997-01-31 Pf Medicament Procede pour ameliorer l'immunogenicite d'un compose immunogene ou d'un haptene et application a la preparation de vaccins
DE19742706B4 (de) * 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9823071D0 (en) * 1998-10-21 1998-12-16 Affibody Technology Ab A method
GB9911287D0 (en) * 1999-05-14 1999-07-14 Affibody Technology Sweden Ab Self-assembling protein structures
US20040001827A1 (en) 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
EP1240337B1 (en) 1999-12-24 2006-08-23 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
CN1169827C (zh) 2001-08-07 2004-10-06 沈阳三生制药股份有限公司 一种增强多肽在体内稳定性药物的生产方法及其应用
WO2003029471A1 (en) * 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of apolipoprotein d
WO2003029462A1 (en) * 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
SE0400274D0 (sv) * 2004-02-09 2004-02-09 Affibody Ab New polypeptide
JP5634008B2 (ja) 2004-04-06 2014-12-03 アフィボディ・アーベー 新規の使用および方法
US7892827B2 (en) 2004-11-26 2011-02-22 Pieris Ag Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
EP2190863B1 (en) * 2007-07-31 2015-09-02 Affibody AB New albumin binding compositions, methods and uses
EP2496598B1 (en) * 2009-11-04 2017-08-02 Affibody AB Her3 binding polypeptides

Also Published As

Publication number Publication date
EP2190863A2 (en) 2010-06-02
CA2694139C (en) 2018-06-05
EP2546261A2 (en) 2013-01-16
US10118949B2 (en) 2018-11-06
US8937153B2 (en) 2015-01-20
US20150158916A1 (en) 2015-06-11
WO2009016043A3 (en) 2009-06-04
EP2546261A3 (en) 2013-08-14
AU2008281913B2 (en) 2013-11-07
CA2694139A1 (en) 2009-02-05
CN104710518A (zh) 2015-06-17
WO2009016043A2 (en) 2009-02-05
CN101765608A (zh) 2010-06-30
DE08786222T1 (de) 2010-11-25
AU2008281913A1 (en) 2009-02-05
HK1211040A1 (en) 2016-05-13
JP5718638B2 (ja) 2015-05-13
CN101765608B (zh) 2015-03-11
US20100273979A1 (en) 2010-10-28
ES2346178T3 (es) 2015-11-02
JP2010534486A (ja) 2010-11-11
EP2190863B1 (en) 2015-09-02
ES2346178T1 (es) 2010-10-13

Similar Documents

Publication Publication Date Title
EP2190863B1 (en) New albumin binding compositions, methods and uses
EP3514169B1 (en) Designed repeat proteins binding to serum albumin
DK2912054T3 (en) Albumin-binding polypeptide
JP2018183171A (ja) アルブミン結合ポリペプチド
WO2024084203A1 (en) Single domain antibodies binding to albumin
EP4598963A1 (en) Ultrastable antibody fragments with a novel disuldide bridge
US11505576B2 (en) Polypeptides based on a scaffold
JP5645155B2 (ja) 分子量マーカー及び分子量マーカーの作製方法
HK40059771A (en) Designed repeat proteins binding to serum albumin
HK40012160B (en) Designed repeat proteins binding to serum albumin
HK40012160A (en) Designed repeat proteins binding to serum albumin
HK1189386A (en) Designed repeat proteins binding to serum albumin